All articles by  

  1. Aimmune begins enrolling egg allergy patients in Phase II study

    Egg allergy is common and can cause severe hypersensitivity reactions, including life-threatening anaphylaxis. The condition affects around six million people…
    Read More…

    22 Aug
  2. Oxurion reports mixed results from Phase IIa DME study

    THR-317 is a humanised antibody targeting placental growth factor (PlGF), while ranibizumab is an anti-vascular endothelial growth factor (VEGF) antibody….
    Read More…

    22 Aug
  3. ViiV’s long-acting HIV regimen passes late-stage trial

    The regimen comprises ViiV’s cabotegravir and Janssen’s rilpivirine. ATLAS-2M compared the antiviral activity and safety of the long-acting regimen given…
    Read More…

    22 Aug
  4. Fulcrum launches Phase IIb trial of losmapimod to treat FSHD

    Losmapimod is a selective inhibitor of p38α/β mitogen-activated protein kinase (MAPK). Fulcrum in-licensed the drug based on its finding that p38α/β…
    Read More…

    21 Aug
  5. Synlogic terminates development of ammonia lowering drug

    The randomised, double-blind, placebo-controlled trial assessed the safety and tolerability of SYNB1020 in a total of 23 participants with cirrhosis…
    Read More…

    21 Aug
  6. Outlook Therapeutics closes enrolment in Phase III wet AMD study

    An ophthalmic formulation, ONS-5010 is a bevacizumab product candidate developed to treat retinal diseases, including wet AMD. Bevacizumab is a…
    Read More…

    21 Aug
  7. Knopp begins study of dexpramipexole in eosinophilic asthma patients

    Dexpramipexole is a small molecule immunologic developed to treat eosinophil-driven diseases such as asthma, hypereosinophilic syndromes (HES), and chronic rhinosinusitis…
    Read More…

    20 Aug
  8. Abivax starts enrolment in Phase IIb ulcerative colitis study

    ABX464 is an anti-inflammatory molecule that binds to the cap-binding complex (CBC) and boosts its function in cellular RNA biogenesis….
    Read More…

    20 Aug
  9. Farxiga meets primary goal in Phase III heart failure trial

    Compared to placebo, the drug showed a statistically-significant and clinically-meaningful decrease in cardiovascular death or the worsening of heart failure…
    Read More…

    20 Aug
  10. Redx Pharma to continue studying RXC004 in Phase I/II trial

    The company has completed dosing of the first cohort with 0.5mg of RXC004 and the corresponding results were reviewed by…
    Read More…

    19 Aug
Close
Close
Close
Globaldata

Identify the key trends in the immuno-oncology market over the next two years

Close

Go Top